🟢 GT Biopharma is trading 5.52% up in pre-market amid continued post-split volatility

GT Biopharma is trading $6.31 (+5.52%) in pre-market amid continued volatility and speculative trading following its reverse split, though the precise catalyst remains unclear.

• GT Biopharma rose after an extremely volatile post-reverse-split session, closing September 9 at $5.98, up 14.13%.
• The 1-for-25 reverse stock split became effective September 8, with split-adjusted trading and a new CUSIP confirmed by Nasdaq.
• No new company-specific announcement or overnight catalyst was identified for September 10.